Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT06769490
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
44 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Acute Myeloid Leukemia
NOT_YET_RECRUITING
NCT07825753
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
225 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Advanced or Metastatic Pancreatic Adenocarcinoma


Advanced or Metastatic Breast Cancer (BC)
RECRUITING
NCT06824168
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
130 Enrollment(s)
64 Study location(s)
INTERVENTIONAL (PHASE2)
Acute Myeloid Leukemia


Leukemia
RECRUITING
NCT06324357
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
768 Enrollment(s)
105 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Metastatic Breast Cancer


Metastatic Gastric Adenocarcinoma


Gastroesophageal Junction Adenocarcinoma


Esophageal Adenocarcinoma


Colorectal Cancer
RECRUITING
NCT06899126
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
686 Enrollment(s)
242 Study location(s)
INTERVENTIONAL (PHASE3)
Non-small Cell Lung Cancer
RECRUITING
NCT07678957
A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
120 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer
RECRUITING
NCT06727227
Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
138 Enrollment(s)
14 Study location(s)
OBSERVATIONAL (None)
Breast Cancer
RECRUITING
NCT06764875
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
840 Enrollment(s)
302 Study location(s)
INTERVENTIONAL (PHASE3)
HER2-positive Gastric Cancer


Gastroesophageal Junction Adenocarcinoma